Dr. Dennis M. Dixon, Chief, Bacteriology and Mycology Branch, Dr. Lanling Zou, Chief of Translational Sciences and Dr. Ping Chen, Director of China Office, Nation Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH) visited TenNor Therapeutics on May 22, 2015. Dr. Zhenkun Ma, Founder and CEO, provided an update on TenNor’s antibacterial R&D program. Guests from NIH expressed great interests in TenNor’s novel dual-action molecule platform and a series of dual-action compounds in its current development pipeline. Dr. Dennis Dixon and Dr. Lanling Zou presented their work titled Antibacterial Resistance: Needs and Opportunities and Resources for the Microbiology & Infectious Diseases Research Community respectively. The parties agreed to further discuss collaborative opportunities in antibacterial area and reached broad consensus in directions for potential collaboration.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com